Romidepsin in the treatment of cutaneous T-cell lymphoma.

about

Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.HDAC inhibitors in kidney development and disease.

P2860

Q35861006-1C795137-4B4E-4344-AB66-AEEE31E27EE4 Q37115414-433A55EC-E96D-4463-99A4-772BE55110E3

P2860

Romidepsin in the treatment of cutaneous T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q35683831

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Romidepsin in the treatment of cutaneous T-cell lymphoma.

@ast

Romidepsin in the treatment of cutaneous T-cell lymphoma.

@en

type

Item

label

Romidepsin in the treatment of cutaneous T-cell lymphoma.

@ast

Romidepsin in the treatment of cutaneous T-cell lymphoma.

@en

prefLabel

Romidepsin in the treatment of cutaneous T-cell lymphoma.

@ast

Romidepsin in the treatment of cutaneous T-cell lymphoma.

@en

P1476

Romidepsin in the treatment of cutaneous T-cell lymphoma.

@en

P2093

Jasmine Zain

http://www.w3.org/2001/XMLSchema#string

Salvia Jain

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics.

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

P304

37-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JBM.S9649

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221789437

http://www.w3.org/2001/XMLSchema#string

P698

22287862

http://www.w3.org/2001/XMLSchema#string

P932

3262342

http://www.w3.org/2001/XMLSchema#string

Romidepsin in the treatment of cutaneous T-cell lymphoma.

about

P2860

P2860

Romidepsin in the treatment of cutaneous T-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932